2C-iP

Chemical compound From Wikipedia, the free encyclopedia

2C-iP, also known as 4-isopropyl-2,5-dimethoxyphenethylamine or as Jelena or Momento, is a psychedelic drug of the phenethylamine and 2C families.[1][2][3] It is taken orally.[1] The drug was first described by 2011[3] and was encountered as a novel designer drug by 2018.[2]

Other names4-Isopropyl-2,5-dimethoxyphenethylamine; 2,5-Dimethoxy-4-isopropylphenethylamine; Jelena; Momento
Routes of
administrationOral[1]
Drug classSerotonin receptor modulator; Serotonergic psychedelic; Hallucinogen
ATC code
  • None
Quick facts Clinical data, Other names ...
2C-iP
Clinical data
Other names4-Isopropyl-2,5-dimethoxyphenethylamine; 2,5-Dimethoxy-4-isopropylphenethylamine; Jelena; Momento
Routes of
administration		Oral[1]
Drug classSerotonin receptor modulator; Serotonergic psychedelic; Hallucinogen
ATC code
  • None
Legal status
Legal status
  • DE: NpSG (Industrial and scientific use only)
  • UK: Class A
Pharmacokinetic data
Duration of action8–12 hours[1]
Identifiers
  • 2-[2,5-dimethoxy-4-(propan-2-yl)phenyl]ethan-1-amine
CAS Number
PubChem CID
ChemSpider
UNII
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC13H21NO2
Molar mass223.316 g·mol−1
3D model (JSmol)
  • COC1=C(C=C(C(=C1)C(C)C)OC)CCN
  • InChI=1S/C13H21NO2/c1-9(2)11-8-12(15-3)10(5-6-14)7-13(11)16-4/h7-9H,5-6,14H2,1-4H3
  • Key:XUGPCRRUMVWELT-UHFFFAOYSA-N
Close

Use and effects

2C-iP's dose is 8 to 25 mg orally and its duration is 8 to 12 hours.[1] It is said that careful dose titration is necessary to avoid overdose.[1] The drug is said to produce a strong sense of heightened awareness of the present moment, resulting in the nickname "Momento", among other effects.[1]

Interactions

See also: Psychedelic drug § Interactions, and Trip killer § Serotonergic psychedelic antidotes

Pharmacology

Pharmacodynamics

2C-iP shows affinity for the serotonin 5-HT2 receptors, including for the serotonin 5-HT2A receptor.[1]

Chemistry

Analogues

Analogues of 2C-iP include 2C-P, 2C-cP, 2C-iBu, 2C-tBu, 2C-D, 2C-E, 2C-T-4, and DOiP, among others.[4][1][2]

History

2C-iP was first described in the scientific literature by Dmitri Ger and colleagues by 2011.[3] It was encountered as a novel designer drug in Sweden in 2018.[2]

Society and culture

Canada

As of October 31, 2016, 2C-iP is a controlled substance (Schedule III) in Canada.[5]

United States

2C-iP is not an explicitly controlled substance in the United States.[6] However, it could be considered a controlled substance under the Federal Analogue Act if intended for human consumption. In addition, it may be considered scheduled as an isomer of 2C-P.[6]

See also

References

External links

Related Articles

Wikiwand AI